Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|January 17, 2017

MilliporeSigma Opens Production Facility in Mollet des Vallès

The company opened a facility in Spain dedicated to the production of meglumine.

On Jan. 17, 2017, MilliporeSigma announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media. The FDA-validated facility in Spain is solely dedicated to the production of meglumine, an amino sugar derived from glucose. As an excipient, meglumine interacts directly with APIs to increase solubility. Therefore, the manufacture of meglumine must meet the same stringent regulatory and quality requirements as APIs, the company said in a statement.

This follows an announcement made by the company on Jan. 10, 2017 on the opening of two new bioprocessing centers. The new locations, in Boston, MA and China, will offer cell-line development services, process development expertise, and non-GMP clinical production services.

Source: MilliporeSigma

 

 


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.